GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » EV-to-EBITDA

MedMira (MedMira) EV-to-EBITDA : -44.31 (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is MedMira EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MedMira's enterprise value is $54.86 Mil. MedMira's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was $-1.24 Mil. Therefore, MedMira's EV-to-EBITDA for today is -44.31.

The historical rank and industry rank for MedMira's EV-to-EBITDA or its related term are showing as below:

MMIRF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -255.57   Med: -10.39   Max: 4513.4
Current: -44.75

During the past 13 years, the highest EV-to-EBITDA of MedMira was 4513.40. The lowest was -255.57. And the median was -10.39.

MMIRF's EV-to-EBITDA is ranked worse than
100% of 449 companies
in the Biotechnology industry
Industry Median: 9.97 vs MMIRF: -44.75

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), MedMira's stock price is $0.06. MedMira's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.004. Therefore, MedMira's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


MedMira EV-to-EBITDA Historical Data

The historical data trend for MedMira's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira EV-to-EBITDA Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.83 -255.57 491.35 -89.46 -43.46

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -71.06 -50.64 -43.46 -40.39 -42.65

Competitive Comparison of MedMira's EV-to-EBITDA

For the Biotechnology subindustry, MedMira's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MedMira's EV-to-EBITDA falls into.



MedMira EV-to-EBITDA Calculation

MedMira's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=54.856/-1.238
=-44.31

MedMira's current Enterprise Value is $54.86 Mil.
MedMira's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (OTCPK:MMIRF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

MedMira's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.06/-0.004
=At Loss

MedMira's share price for today is $0.06.
MedMira's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.004.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


MedMira EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MedMira's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Announces Product Update

By GlobeNewswire GlobeNewswire 12-31-2020

MedMira Introduces VYRA TriDemic

By ACCESSWIRE ACCESSWIRE 12-30-2022

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023